Lipella Pharmaceuticals EBIT

The latest EBIT for LIPO is $-2.6B as of September 2025. That compares with $-2.4B in the prior-year period — down 6.2% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside Lipella Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIPO's EBIT moved from $-2.4B to $-2.6B — a 6.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lipella Pharmaceuticals's operating scale or balance-sheet position.

Against its sector companies, LIPO currently prints $-2.6B for EBIT, while the sector average sits near $-6.4M. That is roughly 39939.0% below the sector mean. Large gaps often invite a closer look at Lipella Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-2.6B for LIPO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting LIPO's EBIT ($-2.6B), review year-over-year change from $-2.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.